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ABSTRACT 
Aim of present work is to develop optimized sustained release dosage form of Bupropion hydrochloride using Formulation by Design (FbD) 
approach. Development and optimization of formulation batches was done by design experiment using Central Composite Design (CCD). 
Tablets were formulated by direct compression technique and evaluated. The impact of independent variables like concentration of 
Hydroxypropyl Methyl Cellulose (HPMC K4M) and  Carbopol (CP 934P) were observed on  dependent variable like hardness of tablet, drug 
release in 12 h (Q12h) and the time for fifty percent release of drug (T50%). Polynomial equations were generated using multiple linear regression 
analysis (MLRA), response surface plots and contour plots were drawn, optimum formulations were selected by brute force method. The 
hardness and Q12h was found in the range of 4.4- 4.7 Kg/cm2 and 88.19- 96.7% respectively, while T50% was found in the range of 3.5- 5.5h. 
Validation of optimization study performed using four confirmatory experimental runs which indicated very high degree of prognostic ability of 
FbD methodology with percentage error varied between -0.024% and 0.024 %. The overlaying of all these plots provided an overlay plot, which 
signified the region of optimization. Thus, central composite design (CCD) is a useful tool in the development of optimized dosage form along 
with the significance of independent variable as well as least investment of money, manpower and time. 
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Introduction 
Bupropion Hydrochloride is an antidepressant of the amino-
ketone class, which is chemically unrelated to tricyclic, 
tetracyclic, serotonin reuptake inhibitor, or other known 
antidepressants. It is somewhat related to 
phenylethylamines 1. Bupropion is an atypical 
antidepressant, which is used for depression as well as for 
smoking cessation. This is the first-line treatment for 
tobacco cessation 2. As per state by Maurizio Fava et al., 
Bupropion is having a lower incidence of weight gain, sexual 
dysfunction and somnolence as compared to all the newly 
discovered antidepressants so far. It is proved to be an 
effective antidepressant, in terms of efficacy as compared to 
Selective Serrotonin Reuptake Inhibitor (SSRI) and other 
antidepressants. This drug can also be used as an adjunctive 
therapy, for the reversal of other antidepressant induced 
sexual dysfunction and also to elevate their efficacy3. The 
depression has out broken on today’s youth, and the reason 
might be their lifestyle. Several studies in elders revealed 
that, especially death in the family and financial problems 
are the most drastic events for depression and the same 
happens in the case of adolescents 4. Since depression and 
smoking are the two most major problems of our society. So, 
such reasons necessitate formulating a Sustained Drug 
Delivery System (SDDS) of Bupropion Hydrochloride, which 
would become a good solution for such problems. Thus a 
floating-bioadhesive formulation of Bupropion 
Hydrochloride could be a most suited form, as the 
bioavailability of the drug will be more predictable and there 
will be a better control in the fluctuations in plasma drug 
concentration5.  
Optimization is a smarter way for substituting the trial and 
error method for formulating any drug delivery system. Trial 
and error method was a traditional method for preparation 
of any formulation and was having certain limitations like; 
time consuming, uneconomical, energy utilising and 
unpredictable6.Thus optimization is the process for finding 
out the most suitable way to develop the best product with 
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the existing sources while taking into account all the factors 
that somehow influence decisions in any experiment 7. The 
word optimize defines itself as perfect, effective and 
functional as possible. “Variables” and “factors” plays vital 
role in the process of optimization. There are two types of 
variables i.e. independent and dependent. Independent 
variables are those, which are not dependent on any other 
value, e.g. concentration of binder, drug to polymer ratio, etc, 
whereas dependent variables are those which depends on 
the concentration of independent variables used. Factors are 
basically assigned variables such as concentration, drug-to-
polymer ratio, temperature etc8. 
Formulation by design (FbD), is one of the optimization 
technique, which specifically make use of design of 
experiment (DoE) in drug formulation development. It is a 
sort of statistical strategy which helps in organizing the 
experiments in such a manner, that the required information 
is obtained as efficiently and precisely as possible. FbD is 
useful in systematically optimizing almost all types of orally 
administered drug delivery systems. Besides screening, this 
method is also advantageous for systematically developing 
products as well as processes9. It acts as a beneficial tool for 
attaining scientific knowledge regarding establishment of 
multi- factorial relationship. Because of all above said 
reasons, this method is gaining popularity for the production 
process in industries9. 
 Materials & methodology 
 Materials: 
Bupropion Hydrochloride was obtained as gift sample from 
Lara Labs, India; HPMC K4M purchased from Colorcon Asia 
Pvt. Ltd., India; CP934P from Zydus Cadila, India; magnesium 
stearate, talc and microcrystalline cellulose from SD Fine, 
India; were also used in the study. All other chemicals used 
were of analytical grade and used as received. Double 
distilled water was used in the study. 
Pre-optimization studies:  
Selection of polymers & their range 
The task of designing the sustained release tablet of 
Bupropion Hydrochloride with desired release 
characteristics began with the selection of potential polymer 
that allows the matrices to sustain the release of drug.  
During preliminary studies, three polymers CP934P, HPMC 
K4M & HPMC K100M were investigated for formulating oral 
sustained tablet of Bupropion Hydrochloride. After intensive 
investigation of various literatures, polymers and excepients 
(Table 1) were selected for pre-optimization studies. 
 
Table 1: List of ingredients and their selected range 
S.No. Ingredient Percentage (%w/w) 
1 Bupropion Hydrochloride 24.7 
2 HPMC K4M 24-55 
3 HPMC K100M 10-61 
4 CP 934P 3-9 
5 Magnesium stearate 2 
6 Talc 1 
7 Microcrystalline Cellulose q.s. 
 
Preparation of sustained release tablets of Bupropion Hydrochloride 
The pre-optimization batches (Batch A and B) were prepared, by using direct compression technique as per the formula stated 
in table 2.  
Table 2: Selected Formula for tablet preparation for pre-optimization 
S.No. Ingredient Batch A Batch B 
1 Bupropion Hydrochloride 24.7 % 24.7% 
2 HPMC K100M 35.5% - 
3 HPMC K4M - 39.5% 
4 CP 934P 6% 6% 
5 Magnesium stearate 2% 2% 
6 Talc 1% 1% 
7 Microcrystalline Cellulose q.s. q.s. 
 
Initially, the drug and the polymers (HPMC K4M and HPMC 
K100M) were passed through mesh # 60 sieve. After that, 
glidant, lubricant and diluents were passed through mesh # 
120 sieve. Then for preparing an appropriate powder blend 
all the ingredients were taken in a V- cone blender and were 
allowed to mix properly for 10 minutes. Finally the tablets 
were prepared by compressing the powder blend in tablet 
compression machine (Rimek Mini Press- I) having 12mm 
flat faced punch10. 
The prepared trial batches were subjected for two 
evaluation parameters i.e. swelling index and in-vitro 
dissolution study. Based on the results of preliminary 
evaluation parameters; the polymers and their ranges were 
selected for further preparation of batches (table 3).  
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Table 3: Formula for Experimental Design 
 
 
 
 
 
 
Therefore various batches (F1- F13) were prepared using 
Central Comopsite Design (CCD), as shown in table 4.  CCD 
with α = 1(face centred) was employed as per the standard 
protocol and thirteen batches were prepared by using 
HPMCK4M and CP934P where centre point was taken in 
quintuplicate (all experimental runs, coded and actual levels 
of independent variables were summarized in table 4)11. In 
the study impact of varying concentration of HPMC K4M (A) 
and CP934P (B) on dependent variables like hardness, Q12h 
and T50. 
 
Table 4: Various batches, with their coded values and actual values 
Batch Code 
Coded Value Actual Value (%) 
HPMC K4M (A)         CP 934P (B) HPMC K4M (A) CP 934P (B) 
F1 -1 -1 24 3 
F2 -1 0 24 6 
F3 -1 +1 24 9 
F4 0 -1 39.5 3 
F5 0 0 39.5 6 
F6 0 +1 39.5 9 
F7 +1 -1 55 3 
F8 +1 0 55 6 
F9 +1 +1 55 9 
F10 0 0 39.5 6 
F11 0 0 39.5 6 
F12 0 0 39.5 6 
F13 0 0 39.5 6 
 
Precompression evaluation 
 Drug-excipients compatibility 
 FT-IR Spectroscopy (Fourier Transform Infrared 
Spectroscopy) 
The IR analysis of pure drug and physical mixture (drug- 
excepient) was conducted. Potassium Bromide disc method 
was utilised for IR analysis. The spectrum was taken by 
scanning the samples individually over a wave number 
range of 4000- 400 cm–1 using Fourier transform infrared 
spectrophotometer (FTIR)12.  
 Evaluation of powder blend 
The prepared powder blend was subjected to various 
evaluation parameters like angle of repose, bulk density 
(BD), tapped density (TD), Carr’s index and Hausner’s ratio. 
 Preparation of sustained Bupropion Hydrochloride 
tablets 
Different tablet batches were prepared by utilising same 
technique as stated in pre optimization. The range of 
polymers selected for preparation of sustained Bupropion 
Hydrochloride tablet shown in table 3 and 4. 
Confirmation of crystalline structure of drug by X- Ray 
Diffractometery 
To analyse the Crystallinity of drug in formulated tablets X 
ray diffraction study was done. A voltage of 40 kV and 
current of 40 mA in the angular range of 10°<2θ<60°, was 
used. After that, step scan mode (step width=0.02°, counting 
time=1 s/step) was used13. 
Physicochemical characterization of tablet 
General appearance and dimensions  
Twenty tablets were randomly selected from the prepared 
batch, to check any discoloration or degradation of drug in 
the tablets by visual method14. 
Thickness of the tablets was measured using vernier caliper 
(Mitech Meterology Ltd., China). The values of thickness 
were used to adjust the initial stages of compression. The 
thickness of tablet was controlled within a limit of ±5% 
variation of a standard value15. 
Weight variation test and Hardness  
The 20 tablets from the batch were selected randomly and 
were weighed individually. After that average weight was 
calculated16. Not more than two of the individual weights 
deviate from the average weight by more than the 
percentage given in the pharmacopoeia and none deviates 
by more than twice that percentage17. 
Mitutoyo digital hardness tester, Japan was utilised for 
determination of hardness18. 
 
In- vitro swelling study 
Single tablet was weighed (W1) and placed in a glass beaker 
containing 200 ml of 0.1N HCl, and maintained in a water 
bath at 37.0 ± 0.5 0C. At regular time intervals, the tablet was 
removed from beaker and the excess surface liquid was 
carefully removed with bloating paper. The swollen tablet 
was weighed again (W2)19.  The swelling index (SI) was 
calculated using eq.1: 
S.No. Ingredients Percentage (%w/w) 
1 Bupropion Hydrochloride 24.7 
2 HPMC K4M 24-55 
3 CP 934P 3-9 
4 Magnesium stearate 2 
5 Talc 1 
6 Microcrystalline cellulose q.s.  
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SI= [(W2-W1)/W1]*100                                       (eq. 1) 
In- vitro Drug Release study 
In-vitro drug release study for the prepared sustained 
release tablets was conducted in 0.1 N HCl for period of 12 
hours using a six-station USP type II (paddle) apparatus 
(Electrolab Pvt. Ltd.) at 37oC± 0.5 0C and 50 rpm speed.  
Sampling was done after every one hour interval; samples of 
10 ml were withdrawn from dissolution medium and 
replaced with fresh medium to maintain the volume 
constant. Absorbance was measured in UV 
spectrophotometer (Shimadzu, Japan) at λ max 298nm 
(Pharmacopoeia). 
Drug release statistics 
Based on phenomenological analysis, the type of release was 
predicted, i.e., whether Fickian, non Fickian or zero-order21. 
Drug release data were subjected to various release models, 
including Higuchi model (eq. 2), which indicates whether the 
drug release mechanism deviates from Fick’s laws and 
shows anomalous behaviour. 
Q＝KH t1/2                      (eq. 2) 
where, Q is the amount of drug release at time t, and KH is 
the Higuchi rate constant. 
The dissolution data was also fitted to Koresmeyer model 
which is used to describe drug release behaviour from 
polymer systems (eqs. 3 and 4) 22. 
Mt/Mα = k.tn                                                              (eq. 3) 
Log (Mt/Mα) = log K+ n Log t                             (eq. 4) 
where ‘Mt’ is the amount of the drug release at time ‘t’, ‘Mα’ 
is the amount of drug release after infinite time and ‘K’ is a 
release rate constant incorporating structural and geometric 
characteristic of the tablet and ‘n’ is the diffusion exponent 
indications for release mechanism.        
Optimisation Data Analysis  
A statistical design was utilized in order to derive the 
relationship between the response variables and the 
independent variables. Design- Expert Version 10 (trial 
version) was utilised for unveiling the relationship between 
dependent and independent variable. In order to get the 
optimized formulation, concentration of both the polymers 
i.e. HPMC K4M (A) & CP 934P (B), were selected as 
independent variables, while the dependent variables 
hardness (Y1), Q12h (Y2) and T50 (Y3) were selected as 
independent variables23.Each factor was set at low, medium 
and high factor. The actual values and coded values are given 
in table 4. 24 
Polynomial models including interaction and quadratic 
terms were generated for all the response variables using 
multiple linear regression analysis (MLRA) approach. The 
general form of the MLRA model is represented as the 
following equation   
y＝β0＋β1A＋β2B＋β3AB＋β4B1＋β5B2＋β6AB2＋β7B1B          (eq. 5)  
Where, β0 is the intercept representing the arithmetic 
average of all quantitative outcomes of 13 runs; β1 to β7 are 
the coefficients computed from the observed experimental 
response values of y; and A and B are the coded levels of the 
independent variable(s). The terms AB and Bi (i＝1 to 2) 
represent the interaction and quadratic terms, respectively.                                       
Validation of optimization analysis 
Four formulations were selected as the confirmatory check-
points to validate by response surface methodology (RSM). 
The observed and predicted responses were critically 
compared. Linear correlation plots were constructed for the 
chosen four optimized formulations, and the percent bias 
(prediction error) was calculated with respect to the 
observed responses25. 
Results & discussion 
Precompression evaluation 
Drug-excepient compatibility 
FT-IR Spectroscopy 
The FTIR spectrum of Bupropion Hydrochloride and its 
physical mixture is shown in Figure 1 and Figure 2. The 
characteristic peaks of Bupropion Hydrochloride are clearly 
shown in both the spectrums. The most prominent peaks are 
obtained at 1690cm-1 & 1691cm-1 of Bupropion 
Hydrochloride and its physical mixture respectively, 
representing aromatic C=C bending, whereas due to 
asymmetric C-H bending, the peak for Bupropion 
Hydrochloride was observed at 1459 cm-1 while the peak for 
Bupropion Hydrochloride  in physical mixture was observed 
at 1457 cm-1. The C-OH stretching in the spectrum was 
observed at peaks 1240 cm- & 1239 cm-1 respectively.
 
 
Figure 1.FTIR spectrum of Bupropion Hydrochloride 
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Figure 2: FTIR Spectrum of physical mixture 
 
Confirmation of crystalline structure of drug by X- Ray 
Diffractometery 
The X-RD spectrum as shown in Figure. 3 for pure drug 
(Bupropion Hydrochloride), reveals its crystalline nature, 
which is evident from its sharp peaks. On the other hand, the 
spectrum of X-RD (Figure. 4) for physical mixture also shows 
the sharp peaks, which confirms its crystalline nature as well 
as also signifies that there is no interaction between drug 
and the excepients. 
 
 
Figure 3: X-RD spectrum of pure drug (Bupropion Hydrochloride) 
 
Figure 4: X-RD spectrum of physical mixture of Bupropion Hydrochloride 
Evaluation of powder blend 
The results of various evaluation parameters of powder 
blend is summarised in table 5. The results of powder blend 
evaluation revealed that the prepared blend exhibits 
excellent packaging properties as well as flowing property. 
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Table 5: Results for evaluation of powder blend 
Batch no. 
Angle of 
repose (°) 
Bulk density 
Tapped 
density 
(g/ml) 
Carr’s index 
Hausner’s 
ratio 
F1 24± 1.08 0.435±1.10 0.535±1.02 0.539±1.02 1.146±1.09 
F2 23± 1.05 0.434±1.12 0.533±1.08 0.535±1.07 1.220±1.12 
F3 24± 1.18 0.437±1.03 0.601±1.09 0.600±1.12 1.159±0.09 
F4 26± 1.05 0.500±1.09 0.549±1.01 0.602±1.10 1.162±1.03 
F5 27±1.08 0.439±1.18 0.537±0.09 0.533±1.05 1.219±1.05 
F6 24± 1.11 0.501±1.12 0.602±1.12 0.534±0.06 1.166±1.01 
F7 25± 1.12 0.505±1.11 0.545±1.06 0.536±1.18 1.189±1.13 
F8 27± 1.07 0.438±1.05 0.567±1.09 0.544±1.12 1.765±1.10 
F9 26± 1.02 0.502±1.12 0.602±1.14 0.549±1.10 1.231±1.05 
F10 25± 1.06 0.505±1.04 0.600±1.13 0.555±1.05 1.229±1.01 
F11 23± 1.01 0.434±1.02 0.545±1.10 0.551±1.12 1.230±1.13 
F12 27± 1.21 0.438±1.06 0.534±1.05 0.546±1.08 1.149±0.09 
F13 26± 1.10 0.503±1.14 0.539±1.08 0.601±1.09 1.156±1.10 
 
Physicochemical characterization of tablet 
The prepared tablets were observed visually. Defects such as 
capping, chipping and lamination were absent. The thickness 
for the tablets of all the formulation (F1- F13) was found in 
the range of 4.29±0.05- 4.61±0.09. 
 
Weight variation test and Hardness 
The percentage deviation from average tablet weight for all 
the tablet was found to be within the specified limits, all 
formulations complied with the test for weight variation 
(table 6) according to the pharmacopoeial specifications.  
The hardness was found in the range of 4.4 to 4.7 kg-cm 
(table 6). 
 
 In- vitro swelling ability 
The in- vitro swelling ability of the tablet was found in the 
range of 0.44-0.81%. The result (Figure5) signified that, the 
increase in the concentration of HPMC K4M was more 
impactful for the swelling of tablet, since HPMC K4M exhibits 
the property of swelling. 
 
 
 
Figure 5: Swelling index of formulated batches 
 
Table 6 Results of physicochemical characterization of tablet 
S.No. 
Dimensions * 
(mm) 
 
Weight variation 
*(mg) 
Hardness 
(kg/cm2) 
Swelling 
ability 
F1 4.44±0.02 607.25±2.39 4.5 0.44 
F2 4.37±0.06 606.25±1.39 4.5 0.46 
F3 4.45±0.10 607.05±1.75 4.6 0.49 
F4 4.29±0.05 605.55±1.75 4.4 0.61 
F5 4.61±0.09 605.05±1.94 4.6 0.63 
F6 4.44±0.03 606.75±2.04 4.5 0.66 
F7 4.40±0.10 604.09±1.94 4.6 0.75 
F8 4.54±0.02 605.41±2.04 4.7 0.77 
F9 4.30±0.06. 606.25±0.19 4.6 0.81 
F10 4.32±0.06 605.15±2.94 4.6 0.63 
F11 4.32±0.06 605.09±1.67 4.6 0.66 
F12 4.32±0.06 605.05±1.90 4.6 0.64 
F13 4.32±0.06 605.14±1.98 4.6 0.64 
*All the values are expressed as mean± SD, n=3 
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In- vitro Drug Release 
The drug release profile of all the batches was studied for 12 
h. The drug release of all formulated batches lies between 
88.2- 96.7%, within 12 h (Figure 6).  Summary of the 
dissolution parameters, i.e. “n” and “k” is indicated in Table 
7. The in- vitro release profile of all the formulations could 
be best expressed by ‘Korsmeyer Peppas equation’.  
As observed from the data of dissolution parameters so 
obtained, the correlation coefficient of all the formulations 
were high (R2 value ranged from 0.9131- 0.9959), which was 
enough to evaluate the drug dissolution behaviour. The 
release exponent (n) was found to be the function of 
polymer used. The n value (ranged from 0.5033- 0.7141) 
indicated non- fickian diffusion mechanism, which is also 
called as anomalous transport. This indicated that 
dissolution was the dominant mechanism of drug release. 
An increase in the amount of both polymers will decrease 
the drug release; hence lower value of drug release constant 
(k), at higher polymer content was obtained. 
 
 
 
Figure 6: Release pattern of formulated batches 
Table 7: Various dissolution parameters for different formulations 
Batch 
Code 
R2 
n k Zero 
order 
Ist order 
Higuchi 
matrix 
Korsmey-
er-Peppas 
Hixson-
crowell 
F1 0.9174 0.9406 0.9131 0.9970 0.9852 0.5033 4.2308 
F2 0.9243 0.9665 0.9137 0.9961 0.9896 0.5336 4.0765 
F3 0.9345 0.9704 0.9154 0.9949 0.9800 0.5876 3.8387 
F4 0.9490 0.9836 0.9146 0.9913 0.9935 0.6192 3.6651 
F5 0.9598 0.9806 0.9148 0.9932 0.9936 0.6531 3.5039 
F6 0.9646 0.9809 0.9158 0.9912 0.9734 0.6810 3.3881 
F7 0.9541 0.9966 0.9203 0.9903 0.9954 0.7122 3.3251 
F8 0.9859 0.9945 0.9191 0.9890 0.9954 0.7045 3.2785 
F9 0.9618 0.9959 0.9191 0.9914 0.9859 0.7141 3.2211 
F10 0.9569 0.9808 0.9138 0.9916 0.9929 0.6321 3.5771 
F11 0.9594 0.9812 0.9144 0.9945 0.9940 0.6460 3.5263 
F12 0.9572 0.9805 0.9138 0.9918 0.9929 0.6328 3.5781 
F13 0.9563 0.9824 0.9138 0.9937 0.9939 0.6284 3.6017 
 
 
Data analysis 
The ANOVA equations obtained from the software was 
helpful in estimating the relationship between independent 
variable and dependent variable. Following equations were 
obtained, for the following three dependent variables: 
Hardness = 4.58 A+ 0.050 B+ 0.025 AB+ 0.084 A2- 0.066 B2+ 
0.025 A2B- 0.025 AB2 (eq.10)                                                                                                                                                                                                                                
Q12h = 88.06- 3.84 A- 1.40 B- 0.15AB+ 0.61 A2+ 0.61 B2- 0.62A2B- 
1.55 AB2   (eq.11) 
T5o= 4.14 +1.25 A+ 0.24 B+ 0.18 AB+ 0.67 A2+ 0.67 B2- 0.16 A2B- 
0.16 AB2    (eq.12) 
From the results of multiple regression analysis, it was 
found that the dependent variables i.e. hardness, Q12h and 
T50 are strongly dependent on independent variables. 
Various response surfaces plotted for the studied response 
showed the effect of polymers in combination on the 
properties and they were known to facilitate an 
understanding of contribution of the variables and their 
interactions. 
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Figure 7 depicts hardness of tablets were increased as the 
concentration of HPMC K4M and CP 934P were increased.  
Figure 7 is showing the effect of CP 934P & HPMC K4M on 
hardness. As per the figure, with increase in both the 
polymers, the strength of the tablet increases. 
At minimum concentration of CP 934P, when HPMC K4M 
increases from lower to higher concentration, the increase in 
hardness is almost linear and the same is applicable for 
increase in the concentration of CP 934P from lower to 
higher concentration, at minimum concentration of HPMC 
K4M, while at higher concentration of HPMC K4M, when CP 
934P increases from lower to higher concentration, the 
initial increase in the hardness is sudden, while it is almost 
static at the end. All these statements are much more, 
strength fully depicted in the contour plot of the same. 
 
  
Figure.7. Response Surface plot & contour plot showing effect of HPMC K4M and CP 934P on Hardness 
 
Figure 8 represented the response surface plot and the contour plot showing the effect of both the polymers on Q12h. Both the 
plots are signifying that on increase in concentration of both the polymers, Q12h is decreasing. At minimum concentration of CP 
934P, when HPMC K4M in increasing from lower to higher concentration, the decrement in Q12 is more prominent as compared 
to CP 934P and the same can be observed through contour plot. This may be due to the fact; HPMC K4M forms a strong viscous 
gel on contact with aqueous media with the gel controlling delivery of the highly water- soluble drug.  
  
Figure. 8: Response Surface plot & contour plot showing effect of HPMC K4M and CP 934P on Drug Release 
 
The response surface plot and contour plot as shown in Figure 9, signifies that on increasing the concentration of both the 
polymers the T50 is also increasing. The value of T50 is increasing with the increment in concentration of HPMC K4M, while with 
CP 934P the value of T50 tends to increase slowly but linearly. The same was observed through contour plot, which is showing 
almost inclining linear contour lines. 
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Figure. 9: Response Surface plot & contour plot showing effect of HPMC K4M and CP 934P on time for 50% release 
3.5 Overlay plot 
The overlay plot obtained by the software shows the area of optimization, which is signified by yellow colour, as shown in 
Figure10. The overlay plot so obtained was useful for the purpose of validation. 
 
Figure 10: Overlay plot showing optimized region 
Validation: 
The validation checkpoints chosen from the overlay plot.. 
The checkpoints taken from the overlay plot showed the 
predicted values of both the independent and dependent 
variables. The percentage error was then calculated between 
the predicted values and observed values, to check the 
accuracy of software. The various validation batches along 
with their predicted values, observed values and percentage 
error is summarised in table 8. The regression coefficient 
between the anticipated and experimental values for 
hardness, Q12 & T50 is represented in Figure11A, Figure11B 
& Figure11C, respectively. 
 
Table 8: Checkpoint Composition, their results and percentage error 
Validation 
batch 
A HPMC K4M 
mg 
B    CP 934P 
mg 
Response variables 
Predicted 
values 
Experimental 
values 
Percentage 
error 
(%) 
VCT1 34.85 7.2 
Hardness (kg/cm2) 4.55 4.8 -0.054 
Q12 (%) 89.11 87.42 0.021 
T50 (h.) 3.89 3.83 0.015 
VCT2 
(optimized) 
31.75 8.7 
Hardness (kg/cm2) 4.54 4.65 -0.024 
Q12 (%) 90.32 89.99 0.003 
T50 (h.) 3.91 3.87 0.010 
VCT3 37.95 6.21 
Hardness (kg/cm2) 4.56 5.00 -0.096 
Q12 (%) 88.44 86.23 0.024 
T50 (h.) 4.01 3.98 0.007 
VCT4 36.4 31.75 
Hardness (kg/cm2) 4.51 4 0.11 
Q12 (%) 90.22 89.55 0.007 
T50 (h.) 3.81 3.75 0.015 
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Conclusion 
The relationship between various process variables chosen 
for the study was successfully determined with the help of 
response surface plots and overlay plot obtained by the 
software. The concentration of the polymers (HPMC K4M & 
CP 934P) were chosen as independent variables, while 
hardness, Q12 & T50, were selected as dependent variables. It 
was observed that on increasing the concentration of both 
the polymers the hardness & T50 was increasing while Q12 
was decreasing, this is because of specific drug release 
controlling power of HPMC K4M & CP 934P. Thus, the study 
was helpful in obtaining the optimized formulation of 
Bupropion.  
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